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Uric Acid (UA) is a product produced from the metabolic breakdown of purines that is 
highly associated with several signaling pathways in pancreatic β-cells. High plasma uric acid 
(hyperuricemia) is associated with gout, insulin resistance, and type 2 diabetes mellitus 
(T2DM). Hyperuricemia can lead to pancreatic β-cell death and decreased insulin sensitivity; 
thus, it could be considered a novel risk factor for the development of T2DM. Expression of 
the transcription factor, Paired Box 4 (PAX4), in pancreatic endocrine progenitor cells plays a 
critical role in inducing β-cell differentiation, and therefore, β-cell plasticity. It has been shown 
that overexpression of PAX4 in pancreatic α-cells caused a conversion of α-β-cell lineage. 
However, the effects of hyperuricemia on PAX4 expression in pancreatic β-cells and their 
consequences are currently unknown. Therefore, this led to my hypothesis that hyperuricemia 
leads to a decrease in PAX4 expression in pancreatic β-cells, which in turn results in a change 
in β-cell plasticity and function. 
 
Human (1.1B4) pancreatic β-cells were used to achieve the aims of this project. We 
investigated how applying hyperuricemic conditions for days affects the expression of PAX4. 
The cells were subjected to an MTT assay (β-cell viability and proliferation), western blot 
analyses (protein expression), RT-qPCR (mRNA expression), and fluorescence 
immunocytochemistry (protein expression detection). We report that 1.1B4 cells had a 
significant decrease in PAX4 protein expression under hyperuricemic conditions (P < 0.05), 
suggesting a loss in β-cell plasticity and function. Furthermore, the transcription factor ARX 
induces pancreatic α-cell differentiation and during β-cell differentiation it is inhibited by 
PAX4. We observed a significant increase in ARX mRNA expression in 1.1B4 cells exposed 
to hyperuricemic conditions (P < 0.05), which indicates a loss in β-cell plasticity, suggesting a 
switch/transdifferentiation to an α-like cell function. 
 iii 
 
In this study, it has been identified that hyperuricemia reduces PAX4 protein expression 
and enhances ARX mRNA expression. Ultimately, this affects the β-cell plasticity inducing 
transdifferentiation to α-like cells. Therefore, PAX4 gene is a potential target that may help 
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Hyperuricemia is a condition caused by high uric acid level in the blood (Roubenoff, 
1990) and is associated with gout, insulin resistance, and type 2 diabetes mellitus (T2DM). Key 
transcription factors (TFs) such as Paired Box 4 (PAX4) and Aristaless Related Homeobox 
(ARX) have been demonstrated to be of important in cellular plasticity of the pancreatic islets 
(α- and β-cells) (Wilcox et al., 2013; Napolitano et al., 2015). Extensive research has 
implicated a strong association between these TFs and the development of Type 2 Diabetes 
Mellitus (T1DM) (Imamura & Maeda, 2011; Wilcox et al., 2013; Cheung et al., 2017), and 
recently,  reprogramming of α-cells to β-like cells demonstrated the potential of therapeutic 
benefits for T2DM (Zhang et al., 2016). However, the underlying mechanism of 
reprogramming β-cells to α-like cells, as well as how it is influenced by hyperuricemia is 
currently still unknown. This research is aiming at targeting PAX4 for therapeutic purposes, 
especially for T2DM. Therefore, this project will investigate the effects of hyperuricemia on 
PAX4 expression in order to potentially develop a therapy using PAX4 as a target to maintain 
pancreatic β-cell plasticity/differentiation, and therefore, preventing the progression and 
development of hyperuremia-induced T2DM.  
 
1.1 Uric Acid and Hyperuricemia 
1.1.1 Uric Acid 
UA is a metabolite produced from the conversion of purines from either exogenous 
(diet) or endogenous sources by xanthine oxidase (XO) (Figure 1.1). Glucose transporter 9 
(GLUT9) that encodes for the SLCA9 gene is the main transporter for UA (Ruiz et al., 2018). 
The excretion of UA occurs mainly in the kidneys ~(70%), and partly in the intestine (~30%) 
(Hediger et al., 2005). The normal serum uric acid (SUA) concentration is maintained between 
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the range of 210 µM and 420 µM (Feig et al., 2006). In lower mammals, UA is further degraded 
by the enzyme uricase into a more water-soluble compound, allantoin (Oda et al., 2002). 
Humans have lost the enzyme uricase due a mutation in the uricase gene during evolution, thus 
preventing any further breakdown of UA (Johnson et al., 2009).  
 
Figure 1.1. Uric acid metabolism. Purine diet, nucleic acids are degraded into adenine and guanine which are 
further broken down to xanthine and hypoxanthine, respectively. Xanthine oxidase further catalyses the reaction 
producing UA. In lower mammals, uricase enzyme is present, thus UA is further degraded to allantoin. Whereas, 
in humans, uricase enzyme is lost due to evolution, further breakdown of UA is not possible. (Abalos, original 
work).  
 
Furthermore, multiple hypotheses on the uricase mutation have also been proposed, 
whereby a higher SUA level was believed to increase intelligence due to similarities with 
several cerebral stimulants (Orowan, 1955). For example, caffeine is found to induce 
neuroprotection in the hippocampus (Aoyama et al., 2011). A study also suggested that the 
mutation occurred to allow the development of walking upright by maintaining blood pressure 
(Johnson et al., 2009), whilst another proposed that it occurred during the famine in Europe in 
order to help maintain glucose homeostasis for survival during starvation (Cicerchi et al., 
2014).  Antioxidants are stable molecules that interreacts with free radicals (ROS) by donating 
electrons reducing its oxidative damage capabilities. Therefore, antioxidants act to delay or 
inhibit cellular damages due to their scavenging properties of free radicals (Halliwell, 1995). 
The mutation also caused UA to become one of the primary antioxidant in the blood due to the 
loss of another antioxidant, vitamin C (Ames et al., 1981). However, other studies argues that 
high UA levels increases the risk of developing diseases  (Johnson et al., 2003) as it increases 
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blood pressure and salt sensitivity (Wang et al., 2017). It also influenced the rapid increase 
prevalence of hyperuricemia (Wallace et al., 2004; Liu et al., 2011), whereby SUA 
concentration exceeds 430 µM (Chizyński & Rózycka, 2005; Bardin & Richette, 2014). 
Adding on, emerging evidence suggests that high UA acts as a prooxidant observed in the 
paradoxical antioxidant-prooxidant pathway (Patterson et al., 2003). The prooxidative role of 
UA (Figure 1.3) causes an increase in the production of reactive oxygen species (ROS) which 
leads to cellular oxidative stress (Schieber & Chandel, 2014; Wang et al., 2017). This further 
induces damages to cell components (DNA (deoxyribonucleic acid), lipids, proteins) (Marnett, 
1999; Stadtman, 2004; Valko et al., 2006), causing cells to self-destruct (apoptosis) (Redza-
Dutordoir & Averill-Bates, 2016).  
 
 
Figure 1.2. Prooxidative role of Uric acid. UA is transported into the cell via GLUT9 and increases reactive 
oxygen species (ROS). ROS damages rough endoplasmic reticulum (RER), deoxyribonucleic acid (DNA), and 
mitochondria. This leads to oxidative stress which ultimately induces apoptosis. (Abalos, original work). 
 
1.1.2 Hyperuricemia 
Hyperuricemia is categorised by either primary or secondary that result in high UA 
production. Primary hyperuricemia is either or both caused by mutations in proteins involved 
in UA metabolism and decreased UA excretion via the kidney or intestine due to mutations in 
UA transporters (Matsuo et al., 2008). Secondary hyperuricemia is  a result of high purine diet 
intake, a factor that is common in other diseases associated with metabolic syndrome (MS) 
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(Schwarzmeier et al., 1974). Interestingly, patients suffering hypertension (MS associated 
disease state) tend to develop hyperuricemia (Choi & Ford, 2007). Hypertensive patients 
usually take diuretic medications used to lower the blood pressure in hypertensive patient, 
however, diuretics (thiazides) are transported by the same transporters as UA (Steele, 1971). 
Thiazides (organic molecules) are exchanged with UA resulting in enhanced UA renal 
absorption, and therefore, increased SUA concentration (Cannon et al., 1966). Furthermore, 
the influence of high purine western diet (fructose, meat and seafood) has further increased the 
development of hyperuricemia. For example, the conversion of fructose to fructose-1-
phosphase conversion increases adenosine triphosphate (ATP) degradation to purines, thus 
increases UA production (Schwarzmeier et al., 1974; Hallfrisch, 1990). When hyperuricemia 
is left untreated, it can lead to certain disease states such inflammation (gout), hypertension 
and diabetes mellitus (DM) (Nakanishi et al., 2003; So & Thorens, 2010). However, the effects 
of hyperuricemia on these disease states are still further investigated. Interestingly, oxidative 
stress is associated with the activation of the inflammatory pathways which results in T2DM 
(Grattagliano et al., 2008). 
 
1.2 Diabetes Mellitus 
DM is a metabolic disease characterised by chronic elevation of blood glucose levels 
(hyperglycemia). There are two types: Type 1 diabetes mellitus (T1DM) is known as an 
autoimmune disease, whereby pancreatic β-cells are recognized as foreign by the immune 
system. This stimulates β-cells to self-destruct, resulting in a decrease in insulin synthesis and 
secretion (Katsarou et al., 2017); T2DM is a chronic condition as a result of insulin resistance 
and decreased viability of β-cells (Alberti & Zimmet, 1998). Previously, deficiency in insulin 
secretion was proposed as a characteristic exclusive to T1DM, whilst decreased response to 
insulin (insulin resistance) was a characteristic restricted to T2DM. Currently, the development 
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of T2DM is now claimed to be a result of a combination of deficiency in insulin secretion 
caused by a loss of β-cell mass and a diminished response to insulin (Butler et al., 2003). 
Ultimately, the combined defects disrupt the regulation of blood glucose homeostasis which 
leads to hyperglycemia and the development of DM (Kahn, 2003). In the last decade, the 
dramatic rise in the incidence of DM has become one of the top problems worldwide. 
According to the International Diabetes Federation (www.idf.org) in 2019, people living with 
diabetes will rise to 700 million by 2045. This upsurge is predominantly caused by the increase 
in T2DM which affects about 90% of all diabetic cases, observed to have more than doubled 
over the last 30 years worldwide (Chen et al., 2012). Therefore, extensive research on the risks, 
development and prognosis of DM is currently being undertaken. Furthermore, the quality and 
span of life of patients living with DM is progressively reduced especially those with T2DM 
as it is associated with increased risk of retinopathy (vision loss), nephropathy (renal failure), 
neuropathy (ulcers and amputations), cardiovascular disease (CVD) and death (Skyler et al., 
2017). T2DM is also caused by other factors such as overweight affecting 20%-40% and strong 
genetic component within family history of DM. The T2DM susceptibility genes identified are 
β-cell function related but it only explains 10%-20% of T2DM heritability. Nonetheless, it 
indicates that changes to β-cell function is the main cause of the disease as it impairs the 
compensatory mechanism towards high demand for insulin, such as in obese individuals 
(Imamura & Maeda, 2011; Boitard et al., 2012; Groop & Pociot, 2014).  Interestingly, the idea 
that there is a strong association between T2DM and hyperuricemia has been supported through 
multiple cross-sectional studies (Clausen et al., 1998; Robles-Cervantes et al., 2011; Woyesa 
et al., 2017). Furthermore, investigations into the underlying molecular mechanism in this 
association  have suggested that UA increases inflammation and reduces viability in β-cells 
(Ruggiero et al., 2006; Jia et al., 2013). The associations of  hyperuricemia with other 
pathologies are continuously being discovered, therefore, determining the SUA concentrations 
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of individuals could potentially be a clinical marker that is of importance in assessing the risks 
of developing T2DM in the future.  
  
1.3 Pancreatic Islets 
A developed pancreas is composed of the exocrine and endocrine compartments. The 
exocrine pancreas contains the acinar and ductal cells that are responsible for secreting 
digestive enzymes, whilst the endocrine pancreas contains cells releasing hormones such as 
insulin or glucagon organised into Islet of Langerhans (Wilcox et al., 2013). The endocrine 
cells involved in DM are the α- and β-cells. The function of the α-cells is to synthesise and 
secrete glucagon into the bloodstream under hypoglycemic conditions (low blood glucose 
concentration). Glucagon acts specifically on the liver, where it stimulates the breakdown of 
glycogen (glycogenolysis) and formation of glucose molecules (gluconeogenesis) in order to 
maintain blood glucose concentration (Figure 1.3) (Briant et al., 2016).  
 
Figure 1.3. Mechanism and effect of α-cells. Under hypoglycemic conditions (low glucose concentration), α-
cells secrete glucagon into the blood stream. Glucagon acts on the liver cell which stimulates glycogenolysis 
(glycogen breakdown) and gluconeogenesis (glucose formation). Ultimately, this maintain blood glucose 
concentration under fasting conditions. (Abalos, original work).  
 
In contrast, β-cells function to synthesise and secrete insulin (Wang et al., 2013) into 
the bloodstream during feeding conditions which stimulates the cellular uptake of glucose via 
the insulin-dependent transporter, GLUT4. This increases e.g. glucose storage in the liver in 
the form of glycogen, resulting in a decrease in blood glucose concentration (Dimitriadis et al., 
2011). Insulin is one of the major hormones that plays a critical role in glucose homeostasis, 
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whereby it is released in response to hyperglycemia (Pfeifer et al., 1981). Glucose is 
transported into the pancreatic β-cells via glucose transporter 1 (GLUT1) (humans) or glucose 
transporter 2 (GLUT2) (rodents) (McCulloch et al., 2011) and converted to ATP via 
glucokinase (Matschinsky et al., 1993). The increase in ATP inhibits the ATP-dependent 
potassium (K+) channels causing an increase in intracellular K+ and therefore, stimulating a β-
cell depolarization. As a result, voltage-gated calcium (Ca2+) channels are activated, inducing 
an influx of Ca2+ which facilitates the synthesis and release of insulin (Figure 1.4) (Safayhi et 
al., 1997; Aguilar-Bryan & Bryan, 1999; Fu et al., 2013).  
 
Figure 1.4. Insulin secretion from pancreatic β-cell. During hyperglycemic conditions (high blood glucose 
concentration), glucose is transported into the β-cell via GLUT1 (humans) or GLUT2 (rodents) and converted to 
ATP by glucokinase. ATP levels rises which inhibits he ATP-dependent K+ channel causing a depolarization. This 
activates the voltage gated Ca2+ channel which stimulates an influx of Ca2+ inducing insulin synthesis and 
secretion. In the bloodstream, insulin acts to regulate the blood glucose levels. (Abalos, original work). 
 
1.4 Pancreatic Islet Cellular Plasticity and Transdifferentiation 
Proliferation of postnatal pancreatic β-cell occurs at low rates (Kassem et al., 2000; 
Meier et al., 2006), which influenced many researchers to question whether β-cell replication 
leads to the production of new β-cells (Salpeter & Dor, 2006). Therefore, the regeneration of 
pancreatic β-cells has been extensively studied as it is a potential strategy to treat diabetes. 
However, multiple approaches and strategies for stimulating endogenous β-cell regeneration, 
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such as via transcription factors and signalling pathways, have been determined to not be 
appropriate for clinical application (Zhong & Jiang, 2019). As α- and β-cells have a close 
lineage relationship, targeting factors involved in cellular plasticity has been recently 
investigated. Cellular plasticity is defined by the ability of a specialised cells to obtain a specific 
characteristic from other cells, which stimulates transdifferentiation (Kim & Lee, 2016), 
whereby the cell converts into another cell in order to compensate the reduction of systemic or 
cellular function (Migliorini et al., 2014). The numerous ways to accomplish 
transdifferentiation includes using a combination of both extracellular growth factors and 
transcription factors together, or individually. Understanding the formation of individual cell 
types will be beneficial in identifying specific molecular factors used to initiate 
transdifferentiation of other cell types. A study suggests that the factors critical for the primary 
organ development will be the most efficient as they are involved at the start of the signalling 
cascade (Tosh & Horb, 2013). Recent investigations have demonstrated a way of potentially 
reprogramming α-cells into β-cells (Bramswig & Kaestner, 2011) targeting transcription 
factors involved in α- and β-cell plasticity. Distinct endocrine cell types are controlled by 
specific transcription factors which includes PAX4 (Sosa-Pineda et al., 1997) and ARX 
(Collombat et al., 2003). Recent evidence has observed the importance of the PAX4 in β-cell 
function (Brun et al., 2004a; Zhang et al., 2016) and ARX in α-cell function (Wilcox et al., 
2013).  
 
1.5 Aristaless Related Homeobox (ARX) and α-cell plasticity 
ARX is expressed in the pancreatic endocrine progenitor restricted to producing 
glucagon-releasing α-cells (Collombat et al., 2003; Mastracci et al., 2011). During pancreatic 
development, ARX binds to the conserved pancreatic enhancer region, which inhibits PAX4, 
and therefore, allowing α-cell differentiation  (Collombat et al., 2003) (Figure 1.5).  
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Figure 1.5. Pancreatic α- and β-cell differentiation. ARX expressed in the endocrine progenitor cells inhibits 
PAX4 to allow α-cell differentiation. PAX4 expressed in the endocrine progenitor cells inhibits ARX to allow β-
cell differentiation. (Abalos, original work).  
 
The expression of ARX was first reported to be in the mouse central nervous system 
(CNS) (Miura et al., 1997), however, in situ hybridization have demonstrated ARX expression 
in the pancreas (Collombat et al., 2003). The loss of ARX in the neonatal pancreas results in a 
decrease in glucagon expression, however, opposite results were observed in adult pancreas 
during short-term ARX ablation (Wilcox et al., 2013). In mice, cells-specific null mutations in 
ARX gene in pancreatic progenitor, endocrine progenitor or germ-line cells demonstrated a 
total loss of α-cells (Collombat et al., 2003; Hancock et al., 2010; Mastracci et al., 2011), 
similar to that observed in pancreas endocrine and exocrine cells of human ARX null mutations 
(Itoh et al., 2010). Adding on, misexpression of ARX in a developing pancreas is capable of 
forcing endocrine progenitors or β-cells to implement an α-cell fate (Collombat et al., 2007). 
Likewise, loss in ARX in glucagon-producing α-cells is observed to impair α-cell identity in 
P5 GKO mice, which also resulted in converted β-like cells via a hormonal intermediate 
(Wilcox et al., 2013). The same study further investigated the authenticity of β-like-cells to 
true β-cells by examining several β-cell markers, such as GLUT2. The results demonstrated 
that a subset of the newly converted cells due to the absence of ARX lead to the activation of 
β-cell markers as well as expressing insulin (Wilcox et al., 2013). However, these were 
observed to occur during pancreatic neonatal period and not in adult pancreas. Surprisingly, a 
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different study implied otherwise, whereby selective  inhibition of the ARX gene in α-cells 
sufficiently converted adult α-cells into β-like-cell at any age. As a result, the loss of ARX is 
suggested to reverse diabetes following a toxin-induced β-cell depletion (Courtney et al., 
2013). When comparing both studies, the experiments and cells used were different which may 
have caused the differing results and conclusion. Altogether, alteration in ARX will affect α-
cells, and therefore, disrupting its function to release glucagon in order to increase blood 
glucose concentration. Although there is evidences that PAX4 expression in pancreatic α-cells 
or endocrine progenitors have caused transdifferentiation of the α-cells to β-like cells (Figure 




Figure 1.6.Pancreatic α-to-β-cell transdifferentiation. When PAX4 expression increases in α-cells, it results in 
transdifferentiation producing β-like cells. (Abalos, original work).  
 
1.6 PAX4 and β-Cell Plasticity 
PAX4 of the PAX gene family of highly conserved transcription factors is involved in 
cell plasticity and organogenesis during embryonic development (Robson et al., 2006; Blake 
& Ziman, 2014). PAX4 is predominantly expressed in endocrine progenitor cells (Greenwood 
et al., 2007; Lorenzo et al., 2015) which plays a critical role in inducing differentiation and 
development of β-cells (Wang et al., 2004; Greenwood et al., 2007), and the master regulator 
for the processes involved in β-cell adaptation (Sosa-Pineda, 2004; Martin-Montalvo et al., 
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2017). During pancreatic development, PAX4 binds to the conserved enhancer region in ARX 
which inhibits transcription to allow β-cell differentiation and function (Figure 1.6) (Collombat 
et al., 2003). The roles were consistent with mouse models expressing low PAX4  resulting in 
low β-cell mass, and therefore, decreased insulin secretion (Sosa-Pineda et al., 1997). Under 
physiological situations such as pregnancy, PAX4+ β-cell subpopulation was observed to 
increase (Brun et al., 2004a) to allow higher blood glucose concentration. Adding on, PAX4 
ectopic expression in human/murine islets which induces the cell cycle gene transcription, is 
found to enhance β-cell proliferation (Brun et al., 2004b; Brun et al., 2004a; He et al., 2011; 
Lorenzo et al., 2015). Modifications of PAX4 will lead to the inability of counteracting high 
insulin demand due to high blood glucose levels (Imamura & Maeda, 2011), which is consistent 
with PAX4 gene dysfunction due to mutations reported to be associated with T1- and T2DM 
diabetes (Cheung et al., 2017). However, the underlying mechanistic regulation of PAX4 
expression has not been clearly established. Interestingly, PAX4, along with Paired Box 6 
(PAX6) are part of group IV of the Pax family, thus they have very similar paired domain (PD) 
and a complete homeodomain (HD) (Smith et al., 1999). PAX6 is known to be modified by 
SUMOylation (Yu et al., 2020), however, there it is currently unknown whether this is also the 
case for PAX4. 
  
1.7 SUMOylation and De-SUMOylation 
SUMOylation (SUMO conjugation) is a posttranslational modification (PTM) involved 
in the regulation of transcription factors through modulating DNA binding, protein stability, 
and cellular localisation (Holmstrom et al., 2003; Chupreta et al., 2007; Garcia-Dominguez & 
Reyes, 2009). Key pancreatic β-cell protein activities such as PDX1, MAFA and glucokinase 
were observed to be regulated by SUMOylation (Sireesh et al., 2014). Small ubiquitin-like 
modifiers (SUMO) or ubiquitin-like proteins (UBLs) play a critical role in DNA transcription 
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and DNA replication (Johnson, 2004; Geiss-Friedlander & Melchior, 2007; Yeh, 2009). The 
four SUMO paralogs of the mammalian cells including SUMO1, SUMO2 and SUMO3. SUMO 
is conjugated via an enzyme-controlled cycle similar to most UBLs. SUMO paralogs are 
synthesised as precursors and processed to become mature by revealing the C-terminal di-
glycine motif. First, SUMO-activating enzyme (E1) activates SUMO1 followed by the transfer 
of the SAE1 (SUMO-activating enzyme subunit 1) and SAE2 by SUMO-conjugating enzyme 
(E2) to the substrate. This initiates an isopeptide bond catalysed by a SUMO protein ligase 
(E3) between the SUMO C-terminal carboxy group and  substrate lysine ɛ-amino group (Figure 
1.7) (Johnson, 2004; Gareau & Lima, 2010). Furthermore, deSUMOylation induces SUMO 
deconjugation, facilitated by Sentrin/SUMO-specific proteases (SENP) which are C48 cysteine 
proteases that are divided up into three families. SENP1 and SENP2 of the first family are 
specific for SUMO1-3, whilst both the second family (SENP3 and SENP5) and third family 
(SENP6 and SENP7)  prefer SUMO2/3 (Li & Hochstrasser, 1999). SENP1, localised in the 
nucleoplasm, contains a nuclear localization signal (N terminus) (Bailey & O'Hare, 2004) and 
nuclear export sequence (C-terminus) (Kim et al., 2005). SENP1 induces de-SUMOylation via 
its hydrolysis activity at the C-terminal and isopeptidase activity (hydrolyses the isopeptide 
bond) (Figure 1.7) (Mukhopadhyay & Dasso, 2007; Yeh, 2009). This is consistent with a study 
in SENP1-/- embryos preventing the processing of SUMO1 precursor, and thus suggesting 
SENP1 as the main SUMO1 C-terminal hydrolase (Cheng et al., 2007).  
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Figure 1.7. The mechanism of SUMOylayion and de-SUMOylation of SUMO1. During SUMOylation, E1 
(SUMO-activating enzyme) activates SUMO1, and E2 (SUMO-conjugating enzyme) transfers SAE1 (SUMO-
activating enzyme subunit 1) and SAE2. This stimulates the formation of the isopeptide bond between the C-
terminal group of SUMO1 and the lysine ɛ-amino group of the substrate. During de-SUMOylation, SENP1 
induces hydrolysis and acts as an isopeptidase which breaks the isopeptide bond between the C-terminal group 
of SUMO1 and the lysine ɛ-amino group of the substrate. (Abalos, original work).  
 
1.8 Summary 
In summary, UA is transported into the cell via GLUT9 and increased concentration will 
result in an increase in ROS stimulating oxidative damage induced-apoptotic pancreatic β-cell 
death. The association between hyperuricemia and PAX4, as well as the link between UA-
induced-oxidative damage with PAX4 has not been investigated. During pancreatic 
development. PAX4 inhibits ARX to allow for a β-cell differentiation and function, which to 
synthesise and secrete insulin. This acts to decrease blood glucose in order maintain glucose 
homeostasis, and therefore, prevent the development of DM (Figure 1.8).  
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Figure 1.8. The summary of the mechanisms in pancreatic β-cell. Uric acid (UA) is transported into the cell via 
GLUT9 causing an increase in reactive oxygen species (ROS) which leads to oxidative damage that induces 
apoptosis and therefore, β-cell death. The effect of UA on PAX4 gene is still unknown, and whether PAX4 gene is 
damaged by oxidative stress is also still unknown. To allow for β-cell differentiation, PAX4 inhibits the 
transcription of ARX gene during pancreatic development. This enables β-cell function to synthesize and secrete 
insulin into the blood stream which contributes to the maintenance of glucose homeostasis. (Abalos, original 
work).  
 
1.9 Rationale, Aims and Hypotheses 
1.9.1 Rationale 
Hyperuricemia is strongly associated with T2DM development (Clausen et al., 1998; 
Robles-Cervantes et al., 2011). Recent evidences have observed the importance of the Paired 
Box 4 (PAX4) in β-cell plasticity and function that is linked to T2DM (Brun et al., 2004a; 
Zhang et al., 2016). However, how hyperuricemia affects β-cell plasticity and function still 
remains unclear, especially its association with PAX4. This is the rationale of my project, 
which allowed the investigated of the mechanisms involved in the changes in pancreatic β-cell 
plasticity. In turn, this will provide further understanding between the association of 
hyperuricemia and the development of T2DM, and therefore help in developing a therapeutic 
strategy for the disease.  
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1.9.2 Hypothesis and Aims 
We hypothesized that hyperuricemia leads to a decrease in PAX-4 expression in pancreatic 
β-cells, which in turn results in a change in β-cell plasticity and function. There were multiples 
aims to this project:  
1) We aim to determine the effects of hyperuricemia on cell viability in human pancreatic 
1.1B4 β-cells. 
2) We aim to determine the changes in PAX4 expression in 1.1B4 cells under 
hyperuricemic conditions. 
3) We aim to examine the changes 1.1B4 cellular plasticity by examining the changes in 
ARX expression.  
4) We aim to determine if PAX4 is SUMOylated in 1.1B4 cells by examining the changes 
in SUMO1 and SENP1 expression. 
5) We aim to assess if the function of 1.1B4 was affected by hyperuricemic conditions, 




The human pancreatic β-cell line (1.1B4) was utilised to achieve the aims of this project. 
The cells were cultured and treated with either normouricemic (300 micromolar (µM)) or 
hyperuricemic (750 µM) conditions for 72 hours (3 days). Total protein was extracted for 
western blot analysis to determine the changes of PAX4 protein expression under 
hyperuricemic conditions. Total RNA isolation from cell pellets was extracted for real-time 
quantitative polymerase chain reaction (RT-qPCR) using the NucleoSpin® RNA Plus protocol 
to determine the changes of expression under hyperuricemic conditions. The appropriate assay 
kit for MTT (dye compound 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromidefor) assay was conducted on cells treated in a 96-well plate, and a micro-plate reader 
was used to measure the absorbance.  
 
2.1 Cell Culture 
2.1.1 Cell Line 
The human pancreatic β-cell lines 1.1B4 was grown and cultured in RMPI (Roswell 
Park Memorial Institute) 1640 filtered medium +10% FBS (Fetal bovine serum) (Sigma-
Aldrich; Cat. No. R6504) in either T25 or T75 flasks. These were incubated at 37°C and 5% 
CO2. The cells were monitored and examined daily via a light microscope to evaluate growth 
rates, confluency and survival. 
 
2.1.2 Passaging 
At 80-100% confluency, cells were passaged, and a splitting rate was determined which 
also depended on the growth rate and utilisation of cells. The material used to passage the cells 
includes 1xPBS (Phosphate-buffered saline) (see appendix Table 5.2), Trypsin (ThermoFisher 
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Scientific Gibco® TrypLE™) and filtered in media which were autoclaved and warmed to 
37°C.  
 
2.1.2.1 T25 Flask of Cells Passaging Techniques 
For each flask, the media was removed and added 1 mL (milliliter) of 1x PBS to rinse the 
media off the cells. Then, 1 mL of TrypLE was added and left for at least 5 minutes, allowing 
cells to detach from the base of the flask. 4 mL of media was added and resuspended to 
guarantee all cells were fully removed from the growth area of the flask. All the contents in the 
flask, such as the media, trypsin and cells were transferred into a tube and centrifuged at 1000 
rpm for 1 min. The cells were resuspended in 1 mL of media after the supernatant was removed. 
The appropriate number of cells (e.g. 1 in 5 splitting rate is 200 µL of cell suspension) was 
suspended and added to a new labeled flask containing 5 mL of media, which is a new cell 
passage (n).  
 
2.1.3 Counting 
The cells were also counted when they had been resuspended in 1 mL of media. 10 µL 
of cells and 10 µL of trypan blue stain (Gibco®) were pipetted into an Eppendorf tube, mixed 
and transferred 10 µL was transferred to a cell slide (ThermoFisher). The plate was then 
inserted into a cell counter (Countess II-FL, Life technologies) that counted and recorded the 
number of live cells to determine the amount of cell suspension to add to each well of a 6-well 
(protein/RNA extraction) or 96-well (MTT assay).  
 
2.1.3.1 Seeding Density and Optimization 
Seeding density optimisation was used due to consistently low protein quantification 
when cells were seeded with a 5x104 well density. Cells were seeded in a 6-well plate with 
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different densities of 5x104, 1x105, 2x105, 3x105, 4x105 and 5x105 cells/well. Cell growth was 
optimized for 4 days (1-day seeding and 3-days treatment) and was monitored daily under a 
light microscope and medium was replaced when required. It was found that the seeding of 
cells at 3x105 cells/well had the ideal confluency at day 4, and therefore, the highest protein 




2.1.4.1 6-Well Plate 
In 6-well plates, the cells were seeded with 3x105 cell density and allowed to grow for 
24 hours (1 day). After a day, the appropriate wells were treated with either 300 µM UA or 750 
µM UA, adding media to a total volume of up to 2 mL, and incubated at 37°C and 5% CO2, for 
another 3 days.  
 
2.1.4.2 Treating a 96-Well Plate 
In 96-well plates, the cells were seeded with 5x104 cells/well and allowed to grow for 1 
day. After a day, the appropriate wells were treated with either 300 µM UA or 750 µM UA, 
adding media to a total volume of up to 100 µL, and incubated at 37°C and 5% CO2, for another 
3 days.  
 
2.2 MTT (metabolic activity) Assay 
An MTT calorimetric assay was utilised to quantify the metabolic activity and 
consequently the relative cell viability or proliferation. The process involved the measurement 
of the activity of the NAD(P)H-dependent cellular oxidoreductase enzyme which caused a 
reduction in tetrazolium dye MTT to formazan (purple colour). The amount of formazan was 
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solubilised and measured which determined the relative quantification of the number of viable 
and proliferation cells. Cytotoxic (damaged) cells usually undergoes cell death or are less 
proliferative, and therefore, it elicits lower amounts of functional mitochondria exhibiting the 
NAD(P)H-dependent cellular oxidoreductase enzyme. 1.1B4 cells in 96-well was utilised for 
the MTT assay and treatments were in triplicates. After 3 days of treatment, the media was 
aspirated and 100 µL fresh 1.1B4 media was added. 10 µL of a 5 mg/mL MTT solution was 
then added and incubated for 4 hours at 37°C. 85 µL of each well was taken out and 50 µL of 
DMSO was added and further incubated for 20 min at 37°C. Formazan dissolved in each well 
was measured at  540 nm with the Molecular Devices® SpectraMax i3x multimode detection 
microplate reader. The averaged absorbance values were used to quantify the dissolved 
formazan.  
 
2.3 Total Protein Extraction 
After a day of cell growth and 3 days treatment in, the cells in 6-well plates were 
harvested. The media of each well was aspirated and washed with 1 x PBS. 100 µL RIPA lysis 
buffer (see appendix 5.6) was added after PBS was removed. This was left for 5 min to allow 
lysis of the cells. The lysate was transferred into an Eppendorf tube and centrifuged for 10 min 
at 10,000 rpm at 4°C to remove debris. The supernatant was transferred into new Eppendorf 
tube and stored at -20°C. The protein samples were then ready for quantification. 
 
2.4 Protein Quantification 
2.4.1 Bradford Assay 
A Bradford assay was conducted to quantify the proteins. A 2 mg/mL Bovine Serum 
Albumin (BSA) (see appendix Table 5.7) (Sigma-Aldrich Cat. No. A1470-100G) stock was 
prepared, which was utilised to perform serial dilutions to form 0.25, 0.5, and 1mg/mL dilution 
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standards (Figure 2.1). 5 µL of each BSA serial dilution (including H2O as a control) and 
protein sample were added into a 96-well plate in triplicates (n = 3). Using the Bio-Rad DC-
Protein Assay Reagent kit (Cat. No. 500-0116), 20 µL of solution S was added to 1 mL of 
solution A to prepare the ASTAR solution. For each well, 25 µL of ASTAR was added 
followed by 200 µL of solution B, also from the Bio-Rad kit. The plate was left at room 
temperature for 15 minutes prior to the analysis with spectrometry (BIO TEK Synergy™ 2 
Multi-Mode Microplate Reader) at 750 nm absorbance. 
 
2.4.2 Analysis 
The values obtained from the absorbance measurements of samples in each well were 
imported into Microsoft Excel. Each triplicate of values was averaged, and using the BSA 
standard dilution averaged absorbance values, a graph in a scatter plot form was produced on 
Microsoft Excel. This generated a linear fit equation used to calculate the protein concentration 
of the unknown samples. Figure 2.2 illustrates an example of a BSA standard curve and linear 
fit equation. 
 
Figure 2.1. Preparation of BSA serial dilution standards. A 2 mL of 2 mg/mL BSA solution was prepared in an 
Eppendorf tube, and 500 µL H2O was added to 1.0, 0.5, and 0.25 mg/mL tubes. A 1 in 2 serial dilution was 
performed by transferring 500 µL from 2.0 mg/mL into 1.0 mg/mL tube 1.0 mg/mL; 500 µL from 1.0 mg/mL tube 
to 0.5 mg/mL tube, and 500 µL from 0.5 mg/mL tube to 0.25 mg/mL, whilst all were mixed thoroughly prior to 




Figure 2.2. Example of a Bradford Assay protein standard curve calculation. The averaged BSA standard 
dilution absorbances was graphed in the form of a scatter plot in Microsoft Excel. This generated a linear fit line, 
used to obtain the equation and R2. 
 
2.5 Western Blotting 
2.5.1 Sample Preparation 
Prior to gel electrophoresis, the appropriate samples were prepared and the loading of 
the total proteins (25 to 100 µg) was determined based on signal. The protein concentrations 
determined by the Bradford assay were utilised to generate samples of loading 100 µg of 
protein in 30 µL. For each sample (in triplicates), 5 µL of BME (loading buffer) (see appendix 
Table 5.10) was added, topped with distilled H2O (dH2O) to a total volume of 30 µL. Table 2.1 
illustrates an example of a sample preparation prior to gel electrophoresis.  
 
Table 2.1. Example of gel electrophoresis sample preparation 
Treatment Sample (µL) Loading Buffer (µL) dH2O (µL) Total (µL) 
300 µM UA 9.988005881 5 14.16519768 30 
750 µM UA 10.83480232 5 14.16519768 30 
 
























2.5.2 Gel Electrophoresis  
2.5.2.1 Gel Preparation 
Gel plates (Bio-Rad) were rinsed with alcohol and set up on a plate stand. For each gel 
plate, distilled water was used to ensure there was no leakage. The appropriate resolving gel 
reagents (Table 2.2) was prepared to produce a 12% resolving gel solution, which was pipetted 
into the gel plates. On top, isopropanol was pipetted to remove air bubbles and prevent 
evaporation. While the gel was left to polymerise for 50 minutes, the appropriate stacking gel 
reagents (Table 2.2) were prepared to produce a 5% stacking gel solution. The solution was 
pipetted superior to the resolving gel after the isopropanol was removed. A 10-well comb was 
inserted into the stacking gel and left to set for 50 minutes. When set, the gel plates were 
wrapped in PBS soaked paper towels and stored (up to 7 days) at 4°C for 24 hours before they 
were used for gel electrophoresis.  
 
Table 2.2: Resolving and stacking gel recipe for SDS PAGE. 
Reagents Resolving Gel (12%) Stacking Gel (5%) 
dH2O (mL) 5.3 3.913 
Lower Tris (mL) 4 - 
Upper Tris (mL) - 1.75 
10% SDS (µL) 160 70 
30% Acrylamide/Bis Sol.  
(Bio-Rad: AA: MBA) (mL) 
6.4 1.19 
10% APS (µL) 160 70 
TEMED (µL) 16 7 
Total (mL) 16 7 
 
 
2.5.2.2 Loading and Running of Gel 
For each gel plate, the 10-well comb was carefully removed and inserted into the Mini-
PROTEAN™ Tetra cell system from BioRad™. 1 x running buffer was poured enough to 
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completely cover the gel. The first well was loaded with 7 µL of Precision Plus Protein Dual 
Colour Standard (Bio-Rad Cat. No. 161-0374) ladder, the wells adjacent to the ladder 30 µL 
of each sample was loaded, Gel electrophoresis was run for 60 min at 140 V (GE Healthcare 
EPS 301 Electrophoresis Power Supply).  
 
2.5.3 Transfer 
2.5.3.1 Trans-Blot Turbo Transfer  
Trans-Blot Turbo™ system from BioRad™ was used for protein transfer. For each gel, 
1 x 4.8 cm2 polyvinylidene difluoride (PVDF) membrane (Immobilon™) and 6 x 4.8 cm2 filter 
paper was cut out.  A transfer sandwich (Figure 2.3) was prepared by placing 3 x filter paper, 
soaked in 1 x transfer buffer (see appendix Table 5.14), on the Trans-Blot Turbo™ system base 
cassette. After the PVDF was soaked for 2 min in methanol for activation, it was further soaked 
in 1 x transfer buffer for 5 min and placed on top of the filter papers. The gel was placed on 
top of membrane and finished off with 3 x filter paper placed superiorly. It was also ensured 
that extra liquid and air bubbles were squeezed and removed within each layer between the 
filter papers, PVDF, and gel. The transfer was run for 20 min at 25V and 1.5A.  
 
 
Figure 2.3. Transfer sandwich for Trans-Blot Turbo. The assembly begins at the base of the cassette with 3 x 
filter paper, which is followed by the PVDF membrane, gel, and finished with 3 x filter paper. 
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2.5.4 Ponceau S Staining 
The protein transfer was assessed by applying Ponceau S staining solution (0.5% [w/v] 
in 1% [v/v] acetic acid) to the membrane for 5 min immediately after the transfer. The solution 
was poured out and the membrane was submerged in dH2O, and imaged using Syngene PXi™ 
imaging system. This indicated how much protein was present on the membrane.  
 
2.5.5 Blocking 
After Ponceau S Staining, the membrane was washed 3 x 5 minutes in 1 x PBST (see 
appendix Table 5.3 ) and blocked with 5% skim milk (see appendix Table 5.13) in PBST for 
~90 minutes on a rocking table.  
 
2.5.6 Application of Antibodies 
After blocking, the membrane was washed 3 x 5 min in PBST followed by 1 x 5 min 
in 1 x PBS. Anti-PAX4 primary antibody (1:1000; PA1-108, Life Technologies) was applied 
and incubated overnight at 4°C on a rocking table. On the next day, the primary antibodies 
were saved, and the membrane was washed 4 x 5 minutes in PBST.  Goat-anti-rabbit-HRP 
secondary antibody (1:25000; Abcam ab671) was then applied for 90 minutes at room 
temperature on a rocking table. After incubating, the secondary antibody was saved, and the 
membrane was washed 3 x 5 minutes in PBST and 3 x 5 minutes in PBS.  
 
2.5.7 Imaging 
After surplus of secondary antibody was completely washed off, Clarity™ Western 
Enhanced Chemiluminescence (ELC) substrate (BioRad™) was used to prepare the ECL prime 
mixture which consists of 300 µL of solution A added to 300 µL of solution. The mixture was 
added to the membrane and ensure that it was fully covered before it was incubated for 5 
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minutes. The ECL substrate will only be usable between 30 and 60 minutes, but the substrate 
can be reapplied when it goes over 60 minutes. The membrane was then placed between clear 
plastic sheets and imaged on the Syngene PXi™ imaging system.  
 
2.5.8 Densitometry 
The blots were imported into Image J™ (National Institutes of Health and the Laboratory 
for Optical and Computational Instrumentation version 1.53a) as jpeg files. Each lane was 
outlined and plotted using a box tool. Peaks were generated and the area underneath was 
measured using the line tool. The values were exported into Microsoft Excel.  The values for 
PAX4 were normalised to the total protein values obtained from Ponceau S staining. 
  
2.6 Total RNA Extraction 
After a day of cell growth and 3 days treatment in, the cells in 6-well plates were 
harvested. The total RNA used for qRT-PCR was extracted according to Nucleospin® RNA 
Plus protocol. The media of each well was aspirated and 350 µL of Buffer LPB was added. 
Ensured that all cells were lysed before it was transferred to Yellow ring columnsand 
centrifuged at 11,000 x 5 for 30 seconds. The yellow ring columns were discarded, and the 
solution in the collecting tubes was kept. 100 µL of Binding Solution BS was added and mixed 
before all the solution was transferred onto the Blue columns and centrifuged at 1,000 x 5 for 
15 seconds.  The collection tubes were discarded, whilst the Blue ring columns were transferred 
to a new collection tubes and went through a series of washes. For the 1st and 2nd wash, the 
collection tubes were discarded, whilst the tubes were transferred into new collection tubes. 
During the 1st wash, 200 µL of Buffer WB1 was added to the tubes and centrifuged at 11,000 
rcf for 15 seconds. During the 2nd wash, 600 µL of Buffer WB2 was added to the tubes and 
centrifuged at 11,000 x 5 for 15 seconds. During the 3rd wash, 250 µL of Buffer WB2 was 
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added to the tubes and centrifuged at 11,000 x 5 for 2 min. The collection tubes were discarded, 
whilst the Blue ring columns were transferred to 1.5 mL tubes. 30 µL of RNase-free H2O was 
added and centrifuged at 11,000 x 5 for 1 min. A further 30 µL of RNase-free H2O was added 
and centrifuged at 11,000 x 5 for 1 min. The RNA samples were then ready for quantification.  
 
2.7 RNA Quantification 
RNA quantification and quality were determined by utilizing the NanoDrop 100 
Spectrophomometer (Thermo Fisher Scientific, IL, USA). The quantity and integrity of each 
RNA sample was determined using the Nucleic Acid test type setting on the NanoDrop 
software (Thermo Fisher Scientific, IL, USA). The absorbance at 260 nm determined the 
presence RNA, whilst the absorbance at 280 nm determined the presence of protein. This 
produced a 260/280 ratio which was indicative of the total RNA purity and considered a “pure” 
total RNA was considered between the of 1.8-2.0. See appendix Table 5.15 for an example of 
a NanoDrop Spectrometry Results.  
 
2.8 Real-time Quantitative Polymerase Chain Reaction (RT-qPCR) 
2.8.1 Reverse Transcription  
After RNA quantification, a reverse transcription for each RNA sample was conducted 
using the Applied Biosystems™ High Capacity cDNA Reverse Transcription Kit. A 2X RT 
master mix (enough for a triplicate of each sample) was prepared. This included 2.0 µL 10X 
RT buffer, 0.8 µL 25X dNTP mix (100 mM), 2.0 µL 10X RT random primers, 1.0 µL 
MultiScribe™ reverse transcriptase, 1.0 µL RNase inhibitor, and 3.2 µL RNase-free H2O, 
bringing it to a total of 10 µL. For each sample (in triplicates), 10 µL of 2X RT master mix was 
added along with 10 µL of RNA sample each and pipetted up and down two times to mix. The 
tube was sealed and briefly centrifuged to remove air bubbles. This was then loaded into 
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Applied Biosystems (STEP ONE, Life Technologies) qPCR machine and followed by thermal 
cycling conditions illustrated in Table 2.3. The cDNA for each RNA sample was synthesized 
and 10x diluted prior to RT-qPCR or stored at -20°C.  
 
Table 2.3. Thermal Cycling conditions for Reverse Transcription 
Settings 1st Step 2nd Step 3rd Step 4th Step 
Temperature (°C)  25 37 85 4 




qPCR was performed to evaluate the mRNA expression of our target genes using 
specific primers. The primers utilised in this study are illustrated in table 2.4. For each primer, 
a reaction mix for all qPCR reactions was prepared in 1.5 mL tubes. For a single qPCR reaction, 
it required 5 µL iTaq Universal SYBR® Green Supermix, 0.4 µL forward primer, 0.4 µL 
reverse primer, and 2.2 µL RNase-free H2O, bringing a total of 8 µL. This was dispensed in a 
96-well aPCR plate (Milti-Max, Cat. No. MUL3890, USA) and 2 µL of the cDNA sample was 
added. The plate was then sealed with a transparent film and vortexed for 30 seconds. The PCR 
run was conducted using the qPCR machine programmed according to the thermal cycling 
protocol shown in Table 2.5.  
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Table 2.4. Primers used for RT-qPCR 
Primers Sequences 
PAX4 FOR: 5’ – CTT TGT GCT GAA GGG CTT TG – 3’  
REV: 5’ – TCC CTG GTC CTC CTG TAA – 3’  
ARX FOR: 5’ – CCA GCC ATG AGC AAT CAG TA – 3’ 
REV: 5’ – TGT CGA TGC AGT AGG AGG A – 3’ 
SUMO1 FOR: 5’ – AAA TTT GAG GGT CTG GAC CAA – 3’ 
REV: 5’ – AGT GAA ATC TTT GGA GTT – 3’ 
SENP1 FOR: 5’ – CTC CAA CTC CCA GTT CTA CTT TC – 3’ 
REV: 5’ – GTT CTT CAA TCT GGC GCA ATC – 3’ 
β-actin FOR: 5’ – CAC TCT TCC AGC CTT CCT TC – 3’ 
REV: 5’ – GTA CAG GTC TTT GCG GAT GT – 3’ 
 
 
Table 2.5. RT-qPCR Thermal cycling protocol 
Setting/Block (Standard) Temperature (°C) Time (seconds) 
Polymerase Activation and DNA Denaturation 95 30 
Denaturation 95 15 
Annealing/Extension and Plate Read 60 60 
Cycles 35-40 




2.8.3 Quantification  
After the qPCR run, the data was collected and transferred to Microsoft Excel. Values 
were first normalised to β-actin (endogenous control). The fold change in mRNA expression 
of the gene of interest relative to 300 µM UA was then determined.   
 
2.9 Immunocytochemistry 
1 x 104 1.1B4 cells/well were seeded and cultured in chamber slides (LAB-TEK 
ThermoFisher) and treated for 3 days. The coverslip was washed 3 x 5 min PBS to remove 
medium. The cells were then fixed for 15 min in 4% paraformaldehyde (Formaldehyde solution 
36.5-38%: Sigma™) in PBS at room temperature. Then, slides were washed 3 x 5 min PBS 
(150µL) to remove the paraformaldehyde. The entry of specific stain was then facilitated by 
the permeabilization of the samples with 1% Triton (Triton®X-100ML solution: Sigma™) in 
PBS for 10 minutes at room temperature. The chambers were then removed. The glass slide 
was washed 3 x 5 min with 150 µL PBS. The slide was then incubated with 10% goat serum 
(Sigma-Aldrich: G9023) for 1 hour to block any non-specific binding. The primary antibodies, 
rabbit anti-PAX4 antibody (1:1000; PA1-108, Life Technologies) and secondary antibodies, 
goat-anti-rabbit Alexa Fluor 488 conjugate (Life Technologies) and goat-anti-mouse Alexa 
Fluor 568 conjugate (Life Technologies) (diluted at 1:100, 110 µL each). These were both 
applied and incubated overnight at 4°C. The primary antibodies were saved, and the glass slide 
was washed 3 x 5 minutes with PBS 150 µL PBS. The glass slide was then incubated with the 
secondary antibodies (diluted 1:1000, 110 µL) for 1 hour at room temperature. The secondary 
antibodies are light sensitive; therefore, application was done with the lights off and the glass 
slide was covered in tin foil. The secondary antibodies were saved, and the glass slide was 
washed 3 x 5 min 150µL PBS also with the lights off. The PBS was removed, and the 
Fluoromount G with including DAPI (Life Technologies) was applied and coverslip was placed 
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slowly on the glass slide (ensuring bubbles were removed). Signals were visualized and imaged 
with fluorescence microscope Olympus BX51 (GM, SC514592).  
 
2.10 Statistical Analysis 
In this project, only 2 treatment groups (300 µM and 750 µM) of normalised values were 
compared for MTT assay, western blot and RT-qPCR. Thus, a 2-tailed unpaired t-test using 
GraphPad Prism (version 7.00 for Windows GraphPad Software, La Jolla California USA, 





3.1 Pancreatic β-cell Metabolic Activity Under Hyperuricemic Conditions 
The regulation of cellular proliferation involves different regulatory molecules 
(hormones and growth factors) that provides the signals to either stimulate or inhibit cellular 
replication in the immediate environment of the cell (Baserga, 1985). When cells are severely 
nutrient deficient (starvation), this leads to an increase in UA (Inoki et al., 2012) which 
stimulates autophagy, a physiological process that orderly degrades cellular components in 
order to increase cellular energy (ATP) (Inoki et al., 2012) and prevent cellular proliferation. 
Hyperuricemia is also known to induce autophagy (Zhang et al., 2020). Here, the study 
investigated the effects of hyperuricemic conditions on cellular proliferation by determining 
the metabolic activity of pancreatic 1.1B4 cells by performing a live cell MTT exposed to either 
300 µM UA or 750 µM UA. The results demonstrated a significant fold reduction in cellular 
metabolic activity under hyperuricemic conditions (750 µM UA) compared to normouricemic 
conditions (300 µM UA) (Figure 3.1; mean ± SEM (standard error of mean); 0.8849 ± 0.02913; 




Figure 3.1. Metabolic activity is significantly reduced in 1.1B4 cells under hyperuricemic conditions. 1.1B4 
cells were exposed to 300 µM UA (normouricemic) or 750 µM UA (hyperuricemic) conditions for 72 hours. 
Cellular metabolic activity changes were measured via a live cell MTT assay. Results determined under 
hyperuricemic conditions were normalized to results determined under normouricemic conditions. Results are 
displayed as mean ± SEM (n (cell passages) = 4). Metabolic activity is significantly reduced under hyperuricemic 
conditions (0.8849 ± 0.02913). *P<0.05, determined by an unpaired 2-tailed-test using GraphPad PRISM. 
 
 
3.2 PAX4 Protein Expression Under Hyperuricemic Conditions 
PAX4 is a key transcription factor involved in the differentiation and cellular plasticity 
of pancreatic β-cells (Sosa-Pineda, 2004; Brun & Gauthier, 2008; Napolitano et al., 2015; 
Martin-Montalvo et al., 2017). PAX4 is known to be driven by activin A via the TGFβ 
signalling pathway (Szabat et al., 2010), which is disturbed by hyperuricemic conditions 
(Sangkop et al., 2016). However, the effect of hyperuricemia on PAX4 expression is still 
unknown. In this study, we investigated our first aim which was to determine whether PAX4 
is expressed and/or altered in pancreatic 1.1B4 cells exposed to hyperuricemic conditions. This 
was achieved by performing western blot analysis using normouricemic conditions as the 
control. PAX4 protein is observed at a molecular weight (MW) of 38 kDa. Densitometry 
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total protein portrayed by Ponceau S staining (Figure 3.2.a). The results demonstrated a 
significant more than 2-fold reduction in PAX4 protein expression under hyperuricemic 
conditions compared to normouricemic conditions (Figure 3.2.b; mean ± SEM; 0.4353 ± 
0.1004; *P = 0.0417). Hence, this suggests that hyperuricemia reduces PAX4 protein levels in 
pancreatic 1.1B4 cells.  
 
 
Figure 3.2. PAX4 protein expression under hyperuricemic conditions is significantly reduced in 1.1B4 cells. 
Total protein lysates of 1.1B4 cells exposed to 300 µM UA and 750 µM UA were extracted and 25 µg of protein 
was analyzed via western blotting. (a) Representative blot of PAX4 protein (38 kDa)(two bands due to different 
splice forms in different tissues) and Ponceau S staining (total protein). Both were quantified using Image J™ 
and PAX4 protein expression was normalised against total protein (300 µM and 750 µM) observed via Ponceau 
S staining. (b) Bar graph of PAX4 protein expression relative to 300 µM UA, expressed as mean ± SEM (n=4). 
PAX4 protein expression is significantly reduced under hyperuricemic conditions (0.4353 ± 0.1004). *P<0.05, 
determined by an unpaired 2-tailed-test using GraphPad PRISM. 
 
3.3 PAX4 mRNA Expression Under Hyperuricemic Conditions 
As hyperuricemia significantly reduced PAX4 protein expression, we further 
investigated PAX4 mRNA expression in 1.1B4 cells exposed to hyperuricemic conditions. 
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and normalised to β-actin. The results demonstrated a no significant change in PAX4 mRNA 
expression under hyperuricemic conditions compared to normouricemic conditions (Figure 
3.3; ns = P = 0.4832). Therefore, this suggests that hyperuricemia has no effect on 
transcriptional regulation of PAX4 mRNA expression in 1.1B4 cells.  
 
 
Figure 3.3. PAX4 mRNA expression in 1.1B4 cells under hyperuricemic conditions. Total RNA of 1.1B4 cells 
exposed to 300 µM UA and 750 µM UA was extracted. PAX4 and β-actin primers were used to perform RT-qPCR 
to assess PAX4 mRNA expression. Data was normalized to β-actin and shown as a fold change relative to 300 
µM UA, expressed as mean ± SEM (n=3). PAX4 mRNA expression in 1.1B4 is not significantly changed under 
hyperuricemic conditions. ns=(P>0.05), determined by an unpaired 2-tailed-test using GraphPad PRISM. 
 
3.4 ARX mRNA Expression Under Hyperuricemic Conditions 
ARX is another key transcription factor that is involved in the differentiation and cellular 
plasticity of pancreatic α-cells (Collombat et al., 2003; Mastracci et al., 2011). However, 
during pancreatic β-cell differentiation, the conserved enhancer region of ARX is bound by 
PAX4 causing an inhibitor effect (Collombat et al., 2005). Although PAX4 mRNA expression 
did not change significantly under hyperuricemic conditions, a significant reduction in PAX4 
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investigated whether the ARX mRNA was expressed or altered in 1.1B4 cells exposed to 
hyperuricemic conditions. This was also achieved by performing an RT-qPCR using 
normouricemic conditions as the control and normalized to β-actin. The results demonstrated 
a significant increase in ARX mRNA expression under hyperuricemic conditions compared to 
normouricemic conditions (Figure 3.4; mean ± SEM; 3.194 ± 0.6145; *P = 0.0438). Thus, it 
suggests that hyperuricemia reduces the inhibitory effect of PAX4 on ARX expression, which 
leads to an enhanced ARX gene expression in 1.1B4 cells.  
 
Figure 3.4. ARX mRNA Total expression is significantly enhanced in 1.1B4 cells under hyperuricemic 
conditions. RNA of 1.1B4 cells exposed to 300 µM UA and 750 µM UA was extracted. ARX and β-actin primers 
were used to perform RT-qPCR to assess ARX mRNA expression. Data was normalized to β-actin and shown as 
a fold change relative to 300 µM UA, expressed as mean ± SEM (n=3). ARX mRNA expression in 1.1B4 is 
significantly increased under hyperuricemic conditions (3.194 ± 0.6145). *P<0.05, determined by an unpaired 
2-tailed-test using GraphPad PRISM. 
 
3.5 SUMO1 mRNA Expression Under Hyperuricemic Conditions 
SUMOylation is a PTM that regulates protein activity location or degradation by forming 
an isopeptide bond between SUMO carboxy group and ɛ-amino lysine of substrate (Yan et al., 
2010). Recent evidence of in silico analysis of PAX4 demonstrated at least four lysine amino 
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is SUMOylated. However, it is still unknown whether PAX4 is SUMOylated under 
hyperuricemic conditions. Therefore, we investigated whether SUMO1 mRNA expression was 
altered in 1.1B4 cells exposed to hyperuricemic conditions. This was achieved by performing 
an RT-qPCR using normouricemic conditions as the control and normalized to β-actin. The 
results demonstrated a no significant change in SUMO1 mRNA expression under 
hyperuricemic conditions compared to normouricemic conditions (Figure 3.5; ns=P=0.0929). 
However, there was a slight a decrease in SUMO1 mRNA expression observed in 1.1B4 cells 
under hyperuricemic conditions (Figure 3.5; mean ± SEM; 0.8239 ± 0.0545). Hence, it suggests 
that hyperuricemia may have an effect on SUMO1 gene expression in 1.1B4 cells.  
 
 
Figure 3.5. SUMO1 mRNA expression shows no significant changes in 1.1B4 cells under hyperuricemic 
conditions. Total RNA of 1.1B4 cells exposed to 300 µM UA and 750 µM UA was extracted. SUMO1 and β-actin 
primers were used to perform an RT-qPCR to assess SUMO1 mRNA expression. Data was normalised to β-actin 
and shown as a fold change relative to 300 µM UA, expressed as mean ± SEM (n=3). ns=P>0.05, determined by 
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3.6 SENP1 mRNA Expression Under Hyperuricemic Conditions 
SENP1 is a protease that is specific at processing both the hydrolysis and isopeptidase 
activity (de-SUMOylation) on the SUMO-formed isopeptide bond between the SUMO 
carboxy group and lysine ɛ-amino group in substrate (Johnson, 2004; Mukhopadhyay & Dasso, 
2007; Yeh, 2009; Gareau & Lima, 2010). SENP1 specifically act on SUMO1 to stimulate de-
SUMOylation. As the previous result showed a hyperuricemia result to slight decrease in 
SUMOylation of PAX4, we also investigated whether PAX4 is de-SUMOylated by SENP1. 
Therefore, we determined whether SENP1 mRNA expression was altered in 1.1B4 cells 
exposed to hyperuricemic conditions. This was achieved by performing an RT-qPCR using 
normouricemic conditions as the control and normalised to β-actin. The results demonstrated 
no significant change in SENP1 mRNA expression under hyperuricemic conditions compared 
to normouricemic conditions (Figure 3.6; ns=P=0.6962). Hence, it suggests that hyperuricemia 
may not have an effect on SENP1 mRNA expression in 1.1B4 cells and consequently, PAX4 
may not be de-SUMOylated under hyperuricemic conditions.  
 38 
 
Figure 3.6. SENP1 mRNA expression exhibits no significant changes in 1.1B4 cells under hyperuricemic 
conditions. Total RNA of 1.1B4 cells exposed to 300 µM UA and 750 µM UA was extracted. SENP1 and β-actin 
primers were used to perform an RT-qPCR to assess SENP1 mRNA expression. Data was normalised to β-actin 
and shown as a fold change relative to 300 µM UA, expressed as mean ± SEM (n=3). ns=(P>0.05), determined 
by an unpaired 2-tailed-test using GraphPad PRISM. 
 
3.7 Glucagon Protein Detection Under Hyperuricemic Conditions 
The differentiation of a pancreatic α-cell is induced by ARX which plays a major role in 
glucose homeostasis as it acts to secrete glucagon (Chung & Levine, 2010). Previous results 
have demonstrated that hyperuricemia significantly increased ARX mRNA expression and 
significantly reduced PAX4 protein expression in 1.1B4 β-cells. This suggests an increase in 
α-cell like plasticity and therefore, glucagon producing α-like cells. We investigated whether 
glucagon and PAX4 proteins are expressed in 1.1B4 cells exposed to hyperuricemic conditions. 
This was achieved by performing a fluorescence immunocytochemistry (ICC) using anti-
PAX4 and anti-GLUCAGON fluorescent antibodies to detect the expression of PAX4 and 
glucagon proteins under a microscope. Due to time limitation, conditions for the ICC could not 
be optimized or quantified leading to inconclusive results. Interestingly, a visual representation 
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expression in 1.1B4 cells under hyperuricemic conditions (Figure 3.7). However, in order to 
form a conclusion, future work on this method must be conducted.  
 
Figure 3.7. Fluorescence immunocytochemistry analysis of PAX4 and glucagon protein expression in 1.1B4 
cells. 1.1B4 cells were exposed to 300 µM UA and 750 µM UA. A co-staining of rabbit anti-PAX4 (green) and 
mouse anti-glucagon (red) antibodies were used to perform a fluorescence immunocytochemistry analysis to 




Overall, 1.1B4 cells exposed to hyperuricemic conditions exhibit changes in cell 
metabolic activity resembling cell viability, as well as expression of protein and mRNA of key 
β-cell transcription factors. In this study, hyperuricemia was demonstrated to decrease cell 
viability; PAX4 protein expression was reduced, however, PAX4 mRNA expression was not 
affected. Nonetheless, this coincided with the reduced ARX mRNA expression, suggestive of 
a decreased inhibition of ARX by PAX4. Adding on, PAX4 SUMOylation and de-
SUMOylation was not affected by hyperuricemia due to the non-significant changes in 
PAX4
G LU C A G O N
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SUMO1 and SENP1 mRNA expression, however, there was a slight decrease in the expression 




The association between hyperuricemia and T2DM development has been established 
(Clausen et al., 1998; Robles-Cervantes et al., 2011), and recent evidence demonstrated a loss 
in β-cell viability when exposed to hyperuricemic conditions (Jia et al., 2013). However, 
whether the loss in β-cell viability is due to a change in β-cell plasticity caused by 
hyperuricemic conditions is currently still unknown. The primary aim of this study was to 
determine the changes in pancreatic β-cell viability under hyperuricemic conditions in order to 
further investigate whether this is caused by a change in β-cell plasticity. Here, we 
demonstrated that hyperuricemia reduces the metabolic activity of pancreatic β-cells, and 
therefore, its cellular viability (Figure 3.1). However, how a change in cellular viability leads 
to a change in cellular plasticity under hyperuricemic conditions is still unclear. PAX4 is 
involved in β-cell differentiation, however, it was still unknown how this is affected by 
hyperuricemia. Therefore, the primary hypothesis of this project was that hyperuricemia leads 
to a change in the expression of PAX4, which in turn result in a change in β-cell plasticity and 
function. In this project, we have confirmed that hyperuricemia decreased PAX4 protein 
expression (Figure 3.2.a). Interestingly, there was no change in PAX4 mRNA expression 
(Figure 3.3)  indicating that the change in PAX4 protein expression is not based on a change 
in transcriptional regulation of the PAX4 gene. As the β-cell plasticity is influenced by the 
inhibitory effect of PAX4 function towards ARX (Collombat et al., 2003), the study also 
determined how the reduction in PAX4 affects ARX under hyperuricemic conditions. Here, 
we report that hyperuricemia caused a significant increase in ARX mRNA expression (Figure 
3.4), which suggest a change in plasticity to a more α-cell like plasticity as ARX plays a critical 
role in pancreatic α-cell differentiation (Collombat et al., 2003; Mastracci et al., 2011). 
Furthermore, as we could not find evidence for transcriptional regulation of PAX4 under 
hyperuricemic conditions, and as recent evidence suggested that PAX4 is SUMOylated 
 42 
stabilizing PAX4 (Lorenzo et al., 2017), we examined the option of this post-translational 
modification of PAX4 and determined the changes in SUMO1 mRNA expression under 
hyperuricemic conditions. This study reports that there was no change in SUMO1 mRNA 
expression under hyperuricemic conditions (Figure 3.5), however, a slight decrease of SUMO1 
mRNA upon exposure of 1.1B4 cells to 750 μM UA was observed suggesting a possible change 
in PAX4 SUMOylation. We further investigated this and determined whether this decrease in 
PAX4 protein expression could be a result of an increase in de-SUMOylation caused by 
SENP1. Likewise, the result demonstrated no change in SENP1 mRNA expression under 
hyperuricemic conditions (Figure 3.6) indicating that the possible change in SUMOylation of 
PAX4 could account for the reduction in PAX4 protein expression.  
 
4.1 Effects of hyperuricemia on β-cell metabolic activity 
This study demonstrated that hyperuricemia reduces the metabolic activity of pancreatic 
β-cells (Figure 3.1). At normal levels of ROS, cells are protected from oxidative damage, 
however, this is reversed when ROS levels increases, and consequently, resulting ultimately in 
apoptosis (Droge, 2002). Hyperuricemia has been shown to increase the production of ROS 
(figure 1.8) (Patterson et al., 2003) mainly observed in preadipocytes, endothelial cells, and 
hepatocytes (HEPG2 cells) (Glantzounis et al., 2005; Sautin et al., 2007; Yu et al., 2010; 
Lanaspa et al., 2012; Sánchez-Lozada et al., 2012). Although pancreatic β-cells expresses low 
amounts of intrinsic antioxidative enzymes, hyperuricemia may still increase ROS production 
and produce the observed effects. Adding on, recent evidence has shown that ROS activates 
the AMP-activated protein kinase (AMPK) in mouse embryonic fibroblasts (MEFs) (Emerling 
et al., 2009). AMPK is a protein kinase activated during cellular starvation due to ATP 
depletion, altering the AMP (adenosine monophosphate):ATP ratio (Oakhill et al., 2009). 
Activated AMPK also acts to inhibit insulin synthesis and secretion (da Silva Xavier et al., 
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2003), affecting β-cell function and glucose homeostasis. Under hyperuricemic conditions 
(Zhang et al., 2013), AMPK in pancreatic β-cells has been found to be activated. Overall, this 
suggests that the effects of hyperuricemia in pancreatic β-cells includes an increase in ROS-
induced oxidative damage, ROS-activated AMPK, and UA-activated AMPK. This leads to a 
reduction in insulin synthesis and secretion affecting the insulin-induced cellular uptake of 
glucose in pancreatic β-cells, and consequently, apoptosis. Overall, hyperuricemia impairs 
cellular metabolic activity and therefore, cellular viability. 
 
4.2 Effects of Hyperuricemia on PAX4 Protein Expression 
The purpose of investigating PAX4 was to determine whether pancreatic β-cell plasticity 
is affected by hyperuricemia. The current study illustrated via western blot analysis that 
hyperuricemia reduced PAX4 protein expression in pancreatic β-cells (Figure 3.1) indicative 
of lower β-cell plasticity. This is a significant finding and will highly contribute to a new 
understanding of normal (under starvation conditions) versus abnormal (under feeding 
conditions or in T2DM) change in β-cell plasticity ultimately leading to T2DM. Although the 
underlying mechanism of how UA affects PAX4 is unknown, a literature suggest that it may 
be linked to the inhibitory effect of UA on activin A and consequently on the transforming 
growth factor (TGFβ) controlling PAX4 expression. Activin A has been demonstrated to 
induce PAX4 expression in pancreatic β-cell lines mediated partly by type IB activin receptor 
(ALK4) (Ueda, 2000), as well in ARX4J-B13 cells via the enhanced transactivation of E47/E12 
proteins (Kanno et al., 2006). Adding on, a study on prostate cancer cell lines demonstrated 
that UA inhibits the effect of activin A (Sangkop et al., 2016). Although the inhibitory effect 
of UA on activin A has not been observed in other cells, it still suggests that hyperuricemia 
may potentially inhibit activin A-induced PAX4 expression. Furthermore, UA-induced ROS-
mediated oxidative stress ultimately result in apoptosis (Schieber & Chandel, 2014; Wang et 
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al., 2017). Recent evidence has shown that overexpression of PAX4 in RIP-B7.1 mice resulted 
in a decreased β-cell apoptosis (Mellado-Gil et al., 2016) suggesting that an under expression 
of PAX4  may potentially induce apoptosis. This further implicates that PAX4 acts to obtain 
cell viability by potentially preventing apoptosis, which coincides with the current result of this 
study in which, hyperuricemia reduced metabolic activity in pancreatic β-cells. Adding on, 
PAX4 plays a critical role in β-cell differentiation to allow β-cells to obtain its function 
(Napolitano et al., 2015). β-cells acts to synthesise and secrete of insulin into the blood stream 
in order to maintain glucose homeostasis (Pfeifer et al., 1981), however this was contradicted 
in a study. A basic helix-loop-helix leucine zipper transcription factor, SREBP1c, is a 
downstream target of PAX4 that allows β-cell growth (Bengoechea-Alonso & Ericsson, 2006; 
Lee et al., 2017), and the study demonstrated that mice under metabolic stress (low energy 
state) showed a decrease in SREBP1c, which led to reduced PAX4 expression and deficient 
insulin secretion (Lee et al., 2019). Therefore, the reduction in PAX4 due to hyperuricemia 
may potentially result in the disruption of glucose homeostasis due to the change in β-cell 
plasticity, and consequently, increase the risk of developing T2DM.  
 
4.3 Effects of Hyperuricemia on PAX4 mRNA Expression 
As there was a change in PAX4 protein expression under hyperuricemic conditions, we 
determined whether hyperuricemia influences the transcriptional regulation of PAX4. Results 
from the RT-qPCR analysis demonstrated that hyperuricemia did not affect PAX4 mRNA 
expression in 1.1B4 cells (Figure 3.3). The paired domain (PD) of PAX4 and PAX6 are similar 
(Smith et al., 1999), and has been established to engage in protein-protein interactions 
modulating the transcriptional activity and transduction of functional proteins into the cells 
(Lorenzo et al., 2017). PAX6 protein expression in mouse insulinoma cells (MIN6 cells) was 
observed to significantly increase under hyperuricemic conditions (Jithran Phol, personal 
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communication). Therefore, transcriptional regulation of PAX4 was not affected by the 
significant decrease in PAX4 proteins under hyperuricemic conditions. Furthermore, PAX4 
also contains a negative regulatory domain which acts to repress the transcription of PAX4. 
The domain will always be active regardless of the cell type, which further suggests that it acts 
directly towards the transcription machinery (Fujitani et al., 1999). According to in vitro 
functional analysis of truncated variants of PAX4, it was found that the truncated PAX4 protein 
binds to the DNA more efficiently compared to the wild type (WT) protein, which surprisingly 
led to the activation of the gene transcription instead of a repressive function (Miyamoto et al., 
2001). Recent evidence has demonstrated that truncated variations of PAX4 have been 
observed in insulinomas (tumour) due to the modifications in the C-terminal domain with 
functional PD (Inoue et al., 1998; Tokuyama et al., 1998; Campbell et al., 1999; Miyamoto et 
al., 2001). Thus, this may explain why PAX4 mRNA expression is not affected by a change in 
PAX4 protein expression in pancreatic β-cells when exposed to hyperuricemia. 
 
4.4 Effects of Hyperuricemia on ARX mRNA 
PAX4 acts and binds to the conserved enhancer region of ARX to inhibit ARX 
expression (Collombat et al., 2003). Our previous results have shown that hyperuricemia 
reduced PAX4 protein expression, and therefore, this study determined whether this results in 
a change in ARX mRNA expression. This current study has demonstrated a novel finding that 
hyperuricemia significantly increases ARX mRNA expression in 1.1B4 cells (Figure 3.4). This 
is further supported by western blot analysis demonstrating a slight increase in ARX protein 
expression in 1.1B4 cells under hyperuricemic conditions (Daniel Perry, personal 
communication). These novel findings suggests that that the inhibitory function of PAX4 
towards ARX is diminished, allowing the expression of ARX. As ARX is involved in 
pancreatic α-cell differentiation (Collombat et al., 2003; Mastracci et al., 2011), the novel 
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results also suggest a change in β-cell plasticity towards an α-like cell plasticity. This in turn 
may induce transdifferentiation into an α-like cell and consequently, an α-cell like function. 
This is consistent with other studies, whereby misexpression of ARX in a developing pancreas 
is capable of forcing endocrine progenitors or β-cells to implement an α-cell fate (Collombat 
et al., 2007). However, the underlying mechanism of how UA affects ARX is still unknown. 
The ARX promoter region of differentiated pancreatic β-cells is methylated by de novo DNA 
methyltransferase (Dnmt3a) (Papizan et al., 2011; Chen & Chan, 2014). During proliferation 
and regeneration of β-cells, the ARX regulatory region is also methylated by another DNA 
methyltransferase, Dnmt1, in order to prevent the decrease in DNA methylation during β-cell 
division (Dhawan et al., 2011; Nishiyama et al., 2016). Recent evidence has shown that in 
cases of a Dnmt1 or Dnmt3a deficiency, both caused β-cells to transdifferentiate to α-like cells 
(Dhawan et al., 2011; Papizan et al., 2011). Adding on, ROS-induced oxidative damage has 
been implicated to modulate DNA methylation (Campos et al., 2007; O'Hagan et al., 2011). 
Therefore, this suggests a possible link, whereby UA-ROS modulation of DNA methylation 
could lead to a change in ARX expression.  
 
4.5 Effects of Hyperuricemia on Glucagon Expression 
A normal α-cell functions to secrete glucagon into the blood stream (Briant et al., 2016). 
As the previous result suggests that the increase in ARX may potentially lead to an increase in 
α-like cell plasticity and function, the current study determined whether there is a change in 
glucagon expression under hyperuricemic conditions. The current study used a visual 
representation of fluorescence immunocytochemistry images that indicate a possible increase 
in glucagon expression in 1.1B4 cells under hyperuricemic conditions (Figure 3.7). However, 
the results have to be further confirmed, and further optimisation of the method and 
quantification may support this result. If this possible increase is to significant, it would support 
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the idea that an increase in ARX in pancreatic β-cells will induce transdifferentiation into α-
like cells under hyperuricemic conditions. In contrast, a loss of ARX in the neonatal pancreas 
results in a decrease in glucagon expression, however, opposite results were observed in the 
adult pancreas during short-term ARX ablation (Wilcox et al., 2013). The finding would also 
suggest that during hyperuricemia, glucagon secretion into the blood would be increased, 
which further disrupt glucose homeostasis.  
 
4.6 Effects of Hyperuricemia on SUMOylation 
PAX6 transcriptional activity is also regulated by SUMOylation via modulation of the 
binding activity (Yan et al., 2010) and the PAX6 SUMOylation site is conserved in PAX4, 
thus suggesting that PAX4 may potentially be SUMOylated (Lorenzo et al., 2017). However, 
there is no current literature that links UA to PAX4 SUMOylation. Therefore, the study 
determined whether PAX4 protein was SUMOylated under hyperuricemic conditions in 
pancreatic β-cell. As PAX4 protein expression under hyperuricemic conditions was reduced, I 
expected to see a decrease SUMO1 mRNA expression. However, the results via RT-qPCR 
illustrated that SUMO1 mRNA expression in 1.1B4 cells was not significantly affected by 
hyperuricemic conditions (Figure 3.5). This suggests that the UA does not affect the formation 
of the isopeptide bond (SUMOylation) between SUMO1 and PAX4. However, a slight 
decrease in SUMO1 mRNA expression under hyperuricemia was observed indicating that an 
isopeptide bond may not be formed between the SUMO1 C-terminal group and the lysine ɛ-
amino group of PAX4. As PAX6 is also SUMOylated by SUMO1 (Yan et al., 2010), and 
PAX6 protein expression in MIN6 cells was observed to significantly increase under 
hyperuricemic conditions it suggests that PAX4 is reduced, whilst PAX6 is enhanced. It further 
implicates that a SUMO1-SUMOylation compensatory-like mechanism, whereby the overall 
expression of SUMO1 is maintained by the opposing changes in PAX4 and PAX6. 
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4.7 Effects of Hyperuricemia on De-SUMOylation  
Further investigation on the mechanism of SUMOylation was conducted through 
investing de-SUMOylation. As SENP1 acts to de-SUMOylate (deconjugate) SUMO1, the 
study determined whether hyperuricemia influences PAX4 de-SUMOylation. This current 
study has demonstrated via RT-qPCR analysis that hyperuricemia did not significant affect 
SENP1 mRNA expression in 1.1B4 cells exposed to hyperuricemic conditions. This suggests 
that UA does not affect the de-SUMOylation activity of SENP1, which involves the 
hydrolysation of the isopeptide bond formed between the SUMO1 and PAX4. Overall, 
hyperuricemia may affect  SUMOylation (SUMO1) but not  de-SUMOylation (SENP1) of 
PAX4. In  support of this idea, overexpression of SUMO1 produced a protective effect on 
insulin secreting beta cell derived line cells (INS-1) against apoptosis, whilst ectopic SENP1 
expression in INS-1 led to sensitisation to IL-1β-induced apoptosis (Hajmrle et al., 2014). 
Therefore, a potential mechanism of which hyperuricemia is associated with SUMO1 and 
SENP1 is via UA-induced-ROS, which coincides with the previous result, suggesting the 
decreased 1.1B4 β-cell viability due to hyperuricemia-induced apoptosis. 
 
4.8 Proposed Mechanism 
Overall, this project has demonstrated novel findings that has helped to form a proposed 
mechanism. During hyperuricemia, pancreatic β-cells experience a high increase in UA 
transport into the cell via GLUT9 (El‐Sheikh et al., 2008; Woodward et al., 2009). As UA is 
established to increase ROS-induced oxidative damage (Schieber & Chandel, 2014; Wang et 
al., 2017), this leads to metabolic stress resulting to a decrease in β-cell metabolic activity, 
which has been confirmed by the MTT assay in this study. Hyperuricemia is associated with 
diabetes, however, how it is linked to β-cell plasticity was still unknown. PAX4 has been the 
main target of this project as it is important for β-cell plasticity, differentiation and function. 
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Through western blotting analysis, this project was able to confirm that hyperuricemia reduces 
PAX4 protein expression in pancreatic β-cells, however, this was not the case for PAX4 mRNA 
expression observed via RT-qPCR analysis. Adding on, the RT-qPCR analysis confirmed that 
ARX mRNA expression is enhanced under hyperuricemic conditions, suggesting a change 
from a β-cell plasticity to an α-like cell plasticity. This change also implicates an α-cell like 
function, however, this could not be confirmed by glucagon expression in ICC experiments, 
yet. This project shows a first attempt to explain the downregulation of PAX4 expression under 
hyperuricemic condition by looking at PAX4 SUMOylation involving SUMO1, and de-
SUMOylated by SENP1 via RT-qPCR analysis. The trend of a possible downregulation of 
SUMO1 expression implies that hyperuricemia changes SUMOylation of PAX4. Overall, this 
project confirmed the hypothesis that hyperuricemia impairs PAX4 protein expression, and 
consequently, β-cell plasticity and function. A mechanism is also proposed by this project, 
whereby an increase in UA result to a decrease in PAX4 protein expression via ROS-induced 
oxidative damage. This results to an increase in ARX expression due to a decrease in the 
inhibitory function of PAX4 to ARX, which leads to a change in an α-like cell plasticity 
inducing transdifferentiation of β-cells to α-like cells. This will ultimately lead to a decrease in 
insulin synthesis and secretion, whilst an increase in glucagon synthesis and secretion. 
Therefore, this increases connects hyperuricemia with the development of T2DM. 
 
Figure 4.1. Proposed mechanism of decreased PAX4 expression in 1.1B4 cells under hyperuricemic conditions. 
Elevated UA levels lead to a decrease in PAX4 and an increase in ARX expression. Ultimately, this leads to a 
change in β-cell plasticity inducing an α-like cell plasticity, which consequently impair the β-cell function, and 
allowing α-like cell function. Thus, a decrease in insulin synthesis and secretion, whilst an increase in glucagon 
synthesis and secretion, which overall disrupts the glucose homeostasis (Abalos, original work).   
 
 50 
4.9 Future Research 
Although this study proposes a possible mechanism, the entire underlying molecular 
mechanisms still needs to be verified and further extended.  The project did not use mouse 
pancreatic β-cell lines such as MIN6 cells; thus, it is still unknown whether the proposed 
mechanism in this project may be species-independent. Therefore, future work on mouse β-
cell lines or even a mouse model will establish whether the proposed mechanism is this current 
study is conserved across species. Animal models will also cover the fact that the pancreatic 
islet is a highly dynamic system involving many different cell types which influence each other. 
There are several additional ways in which this study could have been conducted to further 
support the aim and results Although hyperuricemia is known to result in ROS-induced 
apoptosis, this study did not include experiments to confirm whether pancreatic 1.1B4 β-cells 
exposed to hyperuricemia exhibit apoptosis. The cellular events of apoptosis includes caspase 
activation and DNA fragmentation apoptosis. The cellular events of apoptosis includes caspase 
activation and DNA fragmentation (Elmore, 2007). By conducting an apoptosis cell assay on 
1.1B4 and MIN6 cells exposed 300 µM UA and 750 µM UA, it will quantify the cellular 
events. Activin A drives  the TGFβ-signalling pathway-induced PAX4 expression (Ueda, 
2000) and is known to be disturbed by UA (Sangkop et al., 2016). To determine whether 
hyperuricemia affects activin A-mediated signalling, western blot analysis can be utilised in to 
detect Activin A-mediated expression of PAX4 in 1.1B4 and MIN6 cells exposed to 50 µM 
UA, 300 µM UA or 750 µM UA (according to the species). PAX4 and PAX6 have a similar 
PD (Smith et al., 1999) and both engage in protein-protein interaction (Lorenzo et al., 2017). 
PAX6 is degraded by the proteasome via Trim11 (Pfirrmann et al., 2016). This suggests that 
PAX4 could also be ubiquitinated by Trim11 (Tripartite Motif Containing 11). PAX4 
ubiquitination besides the possible option that it is SUMOylated would explain the decrease of 
PAX4 protein expression under hyperuricemic conditions. Therefore, to determine if PAX4 is 
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also ubiquitinated by Trim11, a pull-down assay on 1.1B4 and MIN6 cells exposed to 
hyperuricemic conditions can be utilized. This uses a bait protein to bind to the beads in a 
column and this will catch other bound proteins. This will be subjected to western blot analysis 
using PAX4 and Trim 11 antibodies in order to determine the protein expression. The ARX 
promoter region is methylated by Dnmt3a (DNA (cytosine-5)-methyltransferase 3a) in 
differentiated β-cells (Papizan et al., 2011; Chen & Chan, 2014). To determine whether the 
DNA methylation of ARX is reduced in 1.1B4 and MIN6 cells under hyperuricemic conditions, 
enzyme-linked immunosorbent assay (ELISA)-based assays can be utilized to assess the DNA 
methylation. This will support the result of this study that ARX mRNA expression in 1.1B4 
cells is increased under hyperuricemic conditions. As observed in the ICC results, optimisation 
and quantification is required in order to produce more conclusive results of glucagon 
expression in 1.1B4 cells, as well as MIN6 cells, under hyperuricemic conditions. Another 
important aspect is that the change in of β-cell plasticity upon hyperuricemic conditions may 
be time-dependent. Thus, exposure to 3 days hyperuricemic conditions may not be enough to 
allow β-cells to fully transdifferentiate to α-like cells. Therefore, doing a time-dependent 
exposure experiment may also provide a better picture of the change in β-cell plasticity. Lastly, 
via personal communication I became aware that there was a significant increase in PAX6 
protein expression in MIN6 cells exposed to hyperuricemic conditions, however, this was not 
tested in 1.1B4 cells. This will further determine the link between the inhibition function of 
PAX4 to PAX6 by binding to G1 (Gosmain et al., 2011).  
 
4.10 Strengths and Limitations 
4.10.1 Strengths 
A major strength of this project was the utilisation of a human pancreatic β-cell line, as 
it allows novel findings to be used for clinical applications. Western blot analysis is an efficient 
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way of investigating the changes in protein expression. The use of Ponceau S staining on each 
blot was used to detect total protein load before the proteins were transferred from the gel to 
the PVDF membrane. This also provided a more objective measure of each condition, which 
was used as a normaliser against each other to allow comparison of protein expression between 
treatment groups. The study utilised three-day-exposure of pancreatic 1.1B4 cells to 
hyperuricemic conditions, which was appropriate as the protocol was based on previous 
experiments on β-cell proliferation and viability which exhibited changes. An important aspect 
of this project was the use of different experimental methods to demonstrate the effects of 
hyperuricemia on PAX4 and its regulation and downstream effects. A western blot analysis 
was used to illustrate the changes of protein expression of PAX4 in cells exposed to 
hyperuricemic conditions. RT-qPCR analysis was used to further investigate whether the 
mRNA expression of PAX4 in pancreatic β-cells was also affected by hyperuricemia. The 
regulation and downstream effects of PAX4 were also investigated via RT-qPCR analysis 
which analysed the expression of ARX, SUMO1, and SENP1 mRNA in pancreatic β-cells. 
 
4.10.2 Limitations  
A major limitation of this project was the lack of utilisation of mouse pancreatic β-cell 
lines. Therefore, it is still unknown whether the proposed mechanism in this project may occur 
in other species. Utilisation of cell lines is a powerful method to employ a mechanism. 
However, the environment of the cell lines are isolated, thus do not completely represent the 
situation. For example, cells are being grown in high-glucose medium which alters the baseline 
characteristics, therefore do not fully obtain non-diabetic human models under normal blood 
glucose concentration (normoglycemia). Instead, this truly represent a model of a human with 
T2DM under high blood glucose concentration (hyperglycemia). Although a primary 
mechanism may be established in human cell lines, the development of a novel mechanism in 
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human models will be challenging due to multiple factors. The project was limited in time to 
conduct time-dependent experiments on other experiments in order to see whether exposure to 
hyperuricemic conditions for 3 days was enough. Furthermore, multiple controls in this project 
were also not used. For example, rat insulinoma cell line (INS-1) could have been used as a 
positive control as it also expresses PAX4, the gene of interest in this project. This positive 
control is important as it determines whether PAX4 will appear. However, this was solved in 
this study by ensuring that band observing the expression of PAX4 correlated to the weight 
indicated in the antibody manufacturers handbook. There was no non-specific bands towards 
PAX4 that appeared throughout the experiments. 
 
4.11 Conclusion 
In conclusion, this novel study has identified two major findings that will be of great 
contribution to the field. The study accepts the hypothesis that hyperuricemia leads to a 
decrease in PAX4 expression. This may lead to a change in pancreatic β-cell plasticity which 
is further supported by the increase in ARX mRNA expression under hyperuricemic 
conditions. This suggest an α-like cell plasticity, which may potentially induce 
transdifferentiation to α-like cells. The results also suggests changes in β-cell function 
supported by the observation that hyperuricemia decreases pancreatic β-cell metabolic activity. 
Therefore, targeting PAX4 expression may help develop a therapeutic strategy via 
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6.1 Recipes: Solutions used in Cell Culture 
Table 6.1. 10x PBS recipe 
Ingredients Amount 
NCl 80 g 
KCl 2.0 g 
Na2HPO4 14.4 g 
KH2PO4 2.48 g 
H2O 1000 mL 
 
Table 6.2. 1x PBS Recipe 
Ingredients Amount 
10x PBS 100 mL 
H2O 900 mL 
 
Table 6.3. 1x PBST Recipe 
Ingredients Amount 
10x PBS 100 mL 
dH2O 900 mL 
Tween  1 mL 
 
Table 6.4. 1.1B4 culture Medium recipe 
Ingredients Amount 
RPMI 1640 (Sigma-Aldrich; Cat. No. …) 1 unit 
NaOH 2 g 
FBS 100 mL 
Anti-anti 10 mL 
H2O 1000 mL 
 
Table 6.5. 5mM uric acid stock solution recipe 
Ingredients Amount 
Uric Acid Sodium Salt (Sigma …) 9.5 g 
1 M NaOH 500 µL 
1x PBS Add to 10 mL 
 pH 7.4 
 
6.2 Recipes: Protein Quantification solutions 
Table 6.6. Lysis buffer recipe 
Ingredients Amount 
RIPA 880 µL 
Complete ULTRA protease inhibitor 100 µL 
PhosphoSTOP phosphatase inhibitor 80 µL 
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Table 6.7. 2mg/mL BSA stock solution recipe 
Ingredients Amount 
BSA (Sigma-Aldrich Cat. No. A1470-100G) 10 mg 
dH2O 5 mL 
 
6.3 Recipes: SDS Gels solutions 
Table 6.8. 1.5M Upper Tris HCl recipe 
Ingredients Amount 
Tris (hydroxylmethyl) 18.117 g 
dH2O 90 mL 
 pH 6.8 
 
Table 6.9. 1.5M Lower Tris HCl recipe 
Ingredients Amount 
Tris (hydroxylmethyl) 22.59 g 
dH2O 90 mL 
 pH 8.8 
 
6.4 Recipes: Western Blot Analysis solutions 
Table 6.10. Loading buffer (BME) recipe 
Ingredients Amount 
Upper tris 4.165 mL 
20% SDS 10 mL 
50% glycerol 20 mL 
Mercaptoethanol (14.3M) 5 mL 
EDTA (200mM) 500 µL 
dH2O  10.38 mL 
Bromophenol blue  Sufficient amount to turn dark blue 
 
Table 6.11. 10x Running Buffer recipe 
Ingredients Amount 
Glycine 140 g 
Tris Base 30 g 
SDS 20 g 
dH2O 1 L 
 
Table 6.12. 1x Running Buffer recipe 
Ingredients Amount 
10x Running Buffer 100 mL 
dH2O  900 mL 
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Table 6.13. 5% Blocking Buffer recipe 
Ingredients Amount 
Skim Milk Powder 2.5 g 
1 x PBST  50 mL 
 
Table 6.14. 1x Transfer Buffer recipe 
Ingredients Amount 
Tris base 7.57 g 
Glycine 36 g 
Methanol 500 mL g 
dH2O 2.4 L 





Table 6.15. Example of a NanoDrop Spectrometry Results 
Sample Name Nucleic Acid (ng/µL) A260 A280 A260/A280 
UT 1 116.022 2.901 1.379 2.103 
UT 2 115.131 2.878 1.368 2.103 
UT 3 115.802 2.895 1.372 2.110 
200µM UA 1 161.757 4.044 1.917 2.110 
200µM UA 2 159.850 3.996 1.892 2.112 
200µM UA 3 160.601 4.015 1.903 2.110 
300µM UA 1 134.844 3.371 1.602 2.105 
300µM UA 2 134.289 3.357 1.585 2.118 
300µM UA 3 134.456 3.361 1.572 2.138 
750µM UA 1 129.275 3.232 3.232 2.120 
750µM UA 2 127.888 3.197 3.197 2.104 
750µM UA 3 128.629 3.216 3.216 2.122 
 
Independent RNA sample results using the NanoDrop 1000 Spectrophotometer.  Shown are the Nucleic Acid 
(ng/µL), absorbance at 260 nm and 280 nm (A260 and A280) and the RNA/DNA (260/280) ratio. A 260/280 ratio 
of ~2.0 is considered “pure” and accepted for RNA.  
 
